Table 1.

Clinical Characteristics of 30 patients with CLL

Pt	Sex	Age, y	Pr Rx	RAI Stage	WBC	IgVH gene	ZAP-70 IHC	B2M	ATM*	p53*
514	F	69	1	0	35	MUT	NEG	1.8	0	0
302	F	59	0	0	27	MUT	ND	2.0	0	0
828	M	65	0	0	33	MUT	NEG	2.0	0	0
724	M	52	0	0	14	MUT	POS	1.7	0	0
295	M	71	0	0	104	MUT	ND	1.5	0	0
607	F	70	0	0	96	MUT	NEG	2.8	0	0
176	M	54	0	0	45	MUT	NEG	1.4	0	0
622	M	49	1	0	45	MUT	POS	1.7	0	0
043	M	52	0	1	75	MUT	POS	3.1	0	0
871	M	52	0	1	150	MUT	ND	3.4	0	0
916	F	60	0	1	62	MUT	NEG	2.4	0	0
417	M	41	0	2	158	MUT	ND	2.5	0	0
033	M	67	0	0	76	UNMUT	POS	2.7	0	0
708	M	54	0	1	44	UNMUT	ND	2.1	ND	ND
425	M	50	0	1	64	UNMUT	POS	2.4	0	29
454	M	57	0	1	89	UNMUT	ND	6.1	38	0
079	F	58	0	1	78	UNMUT	ND	2.1	81	0
315	M	59	0	3	103	UNMUT	NEG	6.5	0	91
195	M	50	1	4	43	UNMUT	NEG	2.2	0	0
820	F	58	0	1	72	ND	POS	2.0	0	0
089	M	66	0	1	45	ND	NEG	2.8	0	0
932	F	78	0	1	113	ND	ND	1.8	ND	ND
504	F	52	0	1	152	ND	POS	4.4	0	67
835	F	75	0	1	121	ND	ND	2.2	0	0
146	M	72	0	1	68	ND	NEG	4.9	34	0
575	F	76	2	1	107	ND	ND	3.9	0	0
002	F	67	0	1	37	ND	POS	1.6	19	0
166	M	63	0	2	75	ND	POS	2.5	0	0
967	M	77	0	4	63	ND	NEG	3.1	0	0
085	F	64	5	4	65	ND	NEG	1.6	0	0

ATM, Ataxia telangiectasia mutated; B2M, b-2-microglobulin level (mg/L); F, female; IgVH, immunoglobulin variable region heavy chain; IHC, immunohistochemistry; M, male; MUT, mutated; ND, not determined; NEG, negative; POS, positive; Pt, patient; Pr Rx, prior treatments; UNMUT, unmutated; WBC, white blood cell count (K/mL of blood); ZAP-70, Zeta-chain-associated protein kinase-70.

^*Percentage of positive cell with cytogenetic abnormality for the corresponding locus.